Mantle cell lymphoma: open trials in China

41 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT06084936
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Trial Treatment · Phase 3 · Hoffmann-La Roche
Beijing Tong Ren Hospital, Capital Medical University, Beijing · The First Hospital of Jilin University, Changchun · West China Hospital of Sichuan University, Chengdu · Chongqing Cancer Hospital, Chongqing · Fujian Provincial Cancer Hospital, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · Guangxi Cancer Hospital of Guangxi Medical University, Nanning · Fudan University Shanghai Cancer Center, Shanghai · The First Affiliated Hospital of China Medical University, Shenyang · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · The First Affiliated Hospital of Zhengzhou University, Zhengzhou · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-11-05
NCT04807881
Phase Ib Clinical Study of Keynatinib
Trial Treatment · Phase 1 · Medolution Ltd.
Peking University Third Hospital, Beijing · Cancer Hospital, Chinese Academy of Medical Sciences, Beijing · West China Hospital，Sichuan University, Chengdu · Fudan University Shanghai Cancer Center, Shanghai
Registry updated 2026-10-29
NCT06742996
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Trial Treatment · Phase 3 · BeOne Medicines
Beijing Cancer Hospital, Beijing · Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu · The First Affiliated Hospital of Chongqing Medical University, Chongqing · Sun Yat-sen University Cancer Center, Guangzhou · Nanfang Hospital, Southern Medical University, Guangzhou · The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan, Hangzhou · Harbin Medical University Cancer Hospital, Harbin · LinYi Cancer Hospital, Linyi · Jiangxi Cancer Hospital, Nanchang · Jiangsu Province Hospital, Nanjing · The Affiliated Hospital of Qingdao University Branch West Coast, Qingdao · Fudan University Shanghai Cancer Center, Shanghai · Liaoning Cancer Hospital and Institute, Shenyang · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Union Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan · Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan · Shaanxi Provincial Peoples Hospital, Xi'an · The affiliated hospital of xuzhou medical university, Xuzhou · The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Registry updated 2026-10-29
NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Trial Treatment · Phase 1/2 · AstraZeneca
Beijing · Guangzhou · Jinan · Tianjin · Zhengzhou
Registry updated 2026-10-28
NCT06697184
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Trial Treatment · Phase 1/2 · BeOne Medicines
Peking University Third Hospital, Beijing · Nanfang Hospital, Southern Medical University, Guangzhou · The First Affiliated Hospital of Soochow University, Suzhou
Registry updated 2026-10-26
NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Trial Treatment · Phase 1/2 · BeOne Medicines
Beijing Chao-Yang Hospital, Capital Medical University, Beijing · Peking University Third Hospital, Beijing · The First Affiliated Hospital of Bengbu Medical University, Bengbu · The First Hospital of Jilin University, Changchun · The Second Xiangya Hospital of Central South University, Changsha · West China Hospital，Sichuan University, Chengdu · Second Affiliated Hospital of Army Medical University (Xinqiao Hospital), Chongqing · Affiliated Zhongshan Hospital of Dalian University, Dalian · Fujian Medical University Union Hospital, Fuzhou · Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou · Sun Yat-sen University Cancer Center, Guangzhou · The First Affiliated Hospital, Zhejiang University School of Medicine Branch Yuhang, Hangzhou · Anhui Provincial Hospital, Hefei · Shandong Cancer Hospital, Jinan · First Affiliated Hospital of Kunming Medical University, Kunming · Jiangxi Province Cancer Hospital, Nanchang · The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang · Jiangsu Province Hospital, Nanjing · The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning · Nanyang Central Hospital, Nanyang · Qingdao Central Hospital, Qingdao · Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai · The First Affiliated Hospital of Soochow University, Suzhou · Shanxi Provincial Cancer Hospital, Taiyuan · Institute of Hematology and Hospital of Blood Disease, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Union Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan · Xiangyang Central Hospital, Xiangyang · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-21
NCT07424833
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Trial Treatment · Phase 1 · Ascentage Pharma Group Inc.
Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-15
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Trial Treatment · Phase 1/2 · BeOne Medicines
Peking Union Medical College Hospital, Beijing · Nanfang Hospital, Southern Medical University, Guangzhou · Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Yichang Central Peoples Hospitaljiangnan Branch, Yichang · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-05
NCT07855016
A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
Trial Treatment · Phase 2 · TransThera Sciences (Nanjing), Inc.
Sun Yat-sen University Cancer Center, Guangzhou · Fudan University Shanghai Cancer Center, Shanghai
Registry updated 2026-10-02
NCT06542250
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Trial Treatment · Phase 1/2 · AstraZeneca
Hangzhou · Shanghai
Registry updated 2026-09-30
NCT06767891
Real-world Study of Acalabrutinib
Research · Ruijin Hospital
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Registry updated 2026-09-08
NCT07788118
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Trial Treatment · Phase 1/2 · Second Affiliated Hospital, Zhejiang University, School of Medicine
The Second Affiliated Hospital,School of Medicine,Zhejiang University, Hangzhou, Zhejiang 310009, Hangzhou
Registry updated 2026-08-26
NCT07784101
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
Trial Treatment · Phase 3 · Beijing InnoCare Pharma Tech Co., Ltd.
Peking University Third Hospital, Beijing · Hunan Cancer Hospital, Changsha · Sichuan Cancer Hospital, Chengdu · West China Hospital of Sichuan University, Chengdu · Xinqiao Hospital of Army Medical University, Chongqing · Chongqing University Cancer Hospital, Chongqing · Fujian Cancer Hospital, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou · Zhejiang Cancer Hospital, Hangzhou · The First Affiliated Hospital of Anhui Medical University, Hefei · Shandong Cancer Hospital, Jinan · Yunnan Cancer Hospital, Kunming · Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing · Fudan University Shanghai Cancer Center, Shanghai · The First Hospital of China Medical University, Shenyang · The Fourth Hospital of Hebei Medical University, Shijiazhuang · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin · Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital, Wuhan · Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · The First Affiliated Hospital of the PLA Air Force Military Medical University (Xijing Hospital), Xian · The Second Affiliated Hospital Of Xi'an Jiaotong University, Xian · Henan Cancer Hospital, Zhengzhou · Henan Provincial People's Hospital, Zhengzhou
Registry updated 2026-08-25
NCT07609862
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Trial Treatment · Phase 1/2 · Guangzhou Lupeng Pharmaceutical Company LTD.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-07-30
NCT07272499
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Trial Treatment · Phase 2 · Ruijin Hospital
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Registry updated 2026-07-28
NCT07082686
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Trial Treatment · Phase 2 · Beijing InnoCare Pharma Tech Co., Ltd.
Peking University Third Hospital, Beijing · The First Hospital of Jilin University, Changchun · Hunan Cancer Hospital, Changsha · West China Hospital of Sichuan University, Chengdu · Sichuan Provincial People's Hospital, Chengdu · Chongqing University Cancer Hospital, Chongqing · The First Affiliated Hospital of Chongqing Medical University, Chongqing · Fujian Medical University Union Hospital, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · Guangdong Provincial People's Hospital, Guangzhou · The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou · The First Affiliated Hospital of Anhui Medical University, Hefei · The First Affiliated Hospital of University of South China, Hengyang · Qilu Hospital of Shandong University, Jinan · Shandong Cancer Hospital, Jinan · Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan · The First Affiliated Hospital of NanChang University, Nanchang · Jiangsu Province Hospital, Nanjing · Guangxi Medical University Cancer Hospital, Nanning · The Affiliated Hospital of Qingdao University, Qingdao · Fudan University Shanghai Cancer Center, Shanghai · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · The Second Affiliated Hospital Of Xi'an Jiaotong University, Xian · The Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang · The Second People's Hospital of Yibin, Yibin · Henan Provincial People's Hospital, Zhengzhou · Henan Cancer Hospital, Zhengzhou · The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Registry updated 2026-07-23
NCT07719556
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
Trial Treatment · Phase 2 · The First Affiliated Hospital with Nanjing Medical University
Changzhou Second People's Hospital, Changzhou · Jiangsu Province Hospital, Nanjing
Registry updated 2026-07-22
NCT07684950
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
Trial Treatment · Phase 2 · Henan Cancer Hospital
Henan Cancer Hospital, Zhengzhou
Registry updated 2026-07-06
NCT07609446
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
Research · The First Affiliated Hospital of Soochow University
The First Affiliated Hospital of Soochow University, Suzhou
Registry updated 2026-05-27
NCT07261163
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, Tianjin · Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-05-13
NCT06852638
CD70-targeted immunoPET Imaging of Malignant Cancers
Trial Treatment · Phase 2 · RenJi Hospital
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai
Registry updated 2026-05-12
NCT07548255
The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL
Trial Treatment · Phase 1 · Ruijin Hospital
Shanghai Ruijin Hospital, Shanghai
Registry updated 2026-04-23
NCT07476378
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
Trial Treatment · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Langfang
Registry updated 2026-03-17
NCT07460362
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial Treatment · Phase 2 · Peking University Third Hospital
Peking University Third Hospital, Beijing
Registry updated 2026-03-10
NCT07377578
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial Treatment · Phase 3 · Guangzhou Lupeng Pharmaceutical Company LTD.
Beijing Cancer Hospital, Beijing · The First Affiliated Hospital of Guangxi Medical University, Nanning
Registry updated 2026-02-06

All Mantle cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error